The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
|Articles|March 22, 2022
Rheumatoid Arthritis Quiz: RA Treat-to-Target
Author(s)Ingrid Torjesen
Treat-to-target is a key strategy used in the treatment of many chronic conditions. Test your knowledge of its use in rheumatoid arthritis.
Advertisement
The American College of Rheumatology recommends against a treat-to-target strategy in which of the following conditions?
Advertisement
Related to this article
August 2026 rheumatology highlights include FDA approval of brepocitinib for dermatomyositis and garetosmab-grts for FOP, and new trial data.
In RA-BRIDGE and RA-BRANCH, baricitinib failed to demonstrate VTE noninferiority in patients with RA enriched for thromboembolic risk factors.
A Phase 2a basket trial produced ACR50 responses in 71% of refractory RA patients at 6 months.
Advertisement
Advertisement